Iovance Biotherapeutics, Inc. (IOVA)
IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress
Iovance posts narrower Q4 loss as Amtagvi sales jump 33%. Shares soar on 50% ORR data and plans for registrational sarcoma study.
Iovance Biotherapeutics: Better Gross Margin And Faster Turnaround Support A Higher Floor (Rating Upgrade)
Iovance Biotherapeutics demonstrates improved Q4 results, with $87M revenue and a 50% gross margin (ex-D&A), but remains high-risk/high-reward. AMTAGVI drives IOVA's prospects, with a modeled $1.6B peak sales and first profit expected in 2028, yet manufacturing and adoption remain challenges. Their cash runway extends into Q3 2027, but dilution risk is material as AMTAGVI is unlikely to generate cash before then; ex-U.S. partnerships are a potential solution.
Iovance Biotherapeutics, Inc. (IOVA) Q4 2025 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (IOVA) Q4 2025 Earnings Call Transcript
Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.26 per share a year ago.
IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential?
Both Iovance Biotherapeutics IOVA and Rigel Pharmaceuticals RIGL are small-cap companies focused on the successful commercialization of their marketed products.
Iovance Biotherapeutics: Bright Prospects For 2026
Iovance Biotherapeutics is reaffirmed as a Buy, driven by Amtagvi's strong efficacy and blockbuster potential in melanoma and lung cancer. IOVA targets significant market expansion, with lung cancer representing a $10B U.S. peak sales opportunity—7x its current melanoma market. Operational risks persist: slow commercial ramp, steep operating losses, and competition from Replimune's RP1, but management expects gross margin gains from in-house manufacturing in 2026.
Iovance Biotherapeutics, Inc. (IOVA) Q3 2025 Earnings Call Transcript
Iovance Biotherapeutics, Inc. ( IOVA ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Sara Pellegrino - Senior Vice President of Investor Relations & Corporate Communications Frederick Vogt - Interim CEO, President, General Counsel, Corporate Secretary & Director Corleen Roche - Chief Financial Officer Daniel Kirby - Chief Commercial Officer Igor Bilinsky - Chief Operating Officer Friedrich Graf Finckenstein - Chief Medical Officer Raj Puri - Chief Regulatory Officer Conference Call Participants Lin Tsai - Jefferies LLC, Research Division Yanan Zhu - Wells Fargo Securities, LLC, Research Division Salim Syed Nicholas Lorusso - TD Cowen, Research Division Xiaochuan Dai - UBS Investment Bank, Research Division Colleen Hanley - Robert W. Baird & Co. Incorporated, Research Division Reni Benjamin - Citizens JMP Securities, LLC, Research Division Presentation Operator Welcome to the Iovance Biotherapeutics Third Quarter and Year-to-Date 2025 Conference Call.
Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Lags Revenue Estimates
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.28 per share a year ago.
Iovance: Q3 Earnings May Smart, But Long Term Bull Thesis Remains In Play
Iovance Biotherapeutics (IOVA) maintains a Buy rating, supported by growing Amtagvi sales, promising efficacy data, and ongoing label expansion opportunities. IOVA's restructuring aims to cut over $100 million in annual costs, extending its cash runway and supporting continued pipeline development despite ongoing heavy losses. The rejection of a key competitor's therapy by the FDA boosts IOVA's market prospects, but profitability remains uncertain due to high costs and slow revenue ramp.
IOVA Stock Drops 6% on $350M Common Stock Offering
Iovance shares slid 6% after unveiling a $350 million stock offering, raising dilution concerns while funding growth plans for Amtagvi and its pipeline.
Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25
IOVA's Amtagvi (lifileucel) launch shows progress with Q2'25 revenue growth, helping rebuild confidence after prior stagnation. Cash burn remains a concern, but the company announced a restructuring with Q2'25 earnings, to help it extend runway to Q4'26. Upcoming data from trials of lifileucel in lung and endometrial cancer could provide upside for the stock, as could a launch of Amtagvi in Canada.
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi
Iovance shares plunge after Q2 miss and voluntary withdrawal of Amtagvi's EU filing, despite strong U.S. sales growth for the therapy.
